Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD

Pulmonary Pharmacology and Therapeutics

Volumn 20, Issue 1, 2007, Pages 60-68

  Jones, N A ^a   Leport, M ^b   Holand, T ^a   Vos, T ^c   Morgan, M ^c   Fink, M ^b   Pruniaux, M P ^b   Berthelier, C ^b   O'Connor, B J ^c   Bertrand, C ^b   Page, C P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PFIZER INC   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; COPD; Lymphocyte; Neutrophil; PDE 4; PDE 7; Phosphodiesterase

Indexed keywords

4 [5 [3 HYDROXYCYCLOHEXYLIMINO] 4 METHYL 4,5 DIHYDRO[1,3,4]THIADIAZOL 2 YL]BENZAMIDE; CHROMOGENIC SUBSTRATE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; LEUKOCYTE ELASTASE; MESSENGER RNA; PF 0332040; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVA; PHOSPHODIESTERASE IVB; PHOSPHODIESTERASE IVC; PHOSPHODIESTERASE IVD; PHOSPHODIESTERASE VII; PHOSPHODIESTERASE VIIA; PHOSPHODIESTERASE VIIB; PHYTOHEMAGGLUTININ; ROLIPRAM; THYMIDINE; TRITIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; MALE; MONONUCLEAR CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSCRIPTION; VENOUS BLOOD;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; AGED; ASTHMA; BENZAMIDES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOCYTE ELASTASE; LEUKOCYTES; MALE; MIDDLE AGED; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PHOSPHODIESTERASE INHIBITORS; PHYTOHEMAGGLUTININS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER; ROLIPRAM; THIADIAZOLES;

EID: 33751043887     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2005.11.010     Document Type: Article

References (30)

1. Nell H., Louw C., Leichtl S., Rathgeb F., Neuhauser M., and Bardin P.G. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Am J Respir Crit Care Med 161 (2000) A200
2. Leichtl S., Syed J., and Bredenbroker D. Efficacy of once-daily roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165 (2002)
3. Li L., Yee C., and Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283 (1999) 848-849
4. Grewe S.R., Chan S.C., and Hanifin J.M. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol 70 (1982) 452-457
5. Chan S.C., Reifsnyder D., Beavo J.A., and Hanifin J.M. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 91 (1993) 1179-1188
6. Tohda Y., Nakahara H., Kubo H., Ohkawa K., Fukuoka M., and Nakajima S. Effects of theophylline on lymphocyte phosphodiesterase activity. Gen Pharmacol 31 (1998) 409-413
7. Landells L.J., Spina D., Souness J.E., O'Connor B.J., and Page C.P. A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects. Pulm Pharmacol Ther 13 (2000) 231-239
8. Tenor H., Staniciu L., Schudt C., Hatzelmann A., Wendel A., Djukanovic R., et al. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 25 (1995) 616-624
9. Gantner F., Tenor H., Gekeler V., Schudt C., Wendel A., and Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 100 (1997) 527-535
10. Ichimura M., and Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem Biophys Res Commun 193 (1993) 985-990
11. Bloom T.J., and Beavo J.A. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 93 (1996) 14188-14192
12. Glavas N.A., Ostenson C., Schaefer J.B., Vasta V., and Beavo J.A. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 98 (2001) 6319-6324
13. Smith S.J., Brookes-Fazakerley S., Donnelly L.E., Barnes P.J., Barnette M.S., and Giembycz M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284 (2003) L279-L289
14. Nakata A., Ogawa K., Sasaki T., Koyama N., Wada K., Kotera J., et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 128 (2002) 460-466
15. Landells L.J., Szilagy C.M., Jones N.A., Banner K.H., Allen J.M., Doherty A., et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 133 (2001) 722-729
16. Vergne F., Bernardelli P., Lorthiois E., Pham N., Proust E., Oliveira C., et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 14 (2004) 4607-4613
17. Vergne F., Bernardelli P., Lorthiois E., Pham N., Proust E., Oliveira C., et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 14 (2004) 4615-4621
18. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
19. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118 (1996) 1945-1958
20. Smith S.J., Cieslinski L.B., Newton R., Donnelly L.E., Fenwick P.S., Nicholson A.G., et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66 (2004) 1679-1689
21. Banner K.H., Roberts N.M., and Page C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 116 (1995) 3169-3174
22. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 69 (2001) 249-315
23. MacKenzie S.J., Baillie G.S., McPhee I., MacKenzie C., Seamons R., McSorley T., et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol 136 (2002) 421-433
24. Barber R., Baillie G.S., Bergmann R., Shepherd M.C., Sepper R., Houslay M.D., et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287 (2004) L332-L343
25. Yang G., McIntyre K.W., Townsend R.M., Shen H.H., Pitts W.J., Dodd J.H., et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171 (2003) 6414-6420
26. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., and Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42 (1991) 869-877
27. Schudt C., Tenor H., and Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 8 (1995) 1179-1183
28. Anderson R., Mahomed A.G., Theron A.J., Ramafi G., and Feldman C. Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. Br J Pharmacol 124 (1998) 547-555
29. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284 (1998) 420-426
30. Jones N.A., Boswell-Smith V., Lever R., and Page C.P. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18 (2005) 93-101